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http:WHAT THIS PAPER ADDS
Only a few studies have estimated associations between vascular function and prognosis in the setting of pe-
ripheral arterial disease (PAD). Whether changes in arterial stiffness can predict all-cause and cardiovascular
disease mortality in patients with symptomatic PAD has never been investigated. The present study is the ﬁrst to
demonstrate a direct independent relationship between small artery elasticity and all-cause and cardiovascular
disease mortality in a cohort of symptomatic patients with advanced atherosclerosis. This ﬁnding further sup-
ports the relevance of arterial dysfunction in progression of cardiovascular disease and suggests that symp-
tomatic PAD patients with reduced small artery elasticity continue to be at an increased risk for all-cause and
cardiovascular disease mortality.Objectives: Arterial stiffness (AS) is increasingly recognized as an independent risk factor in different high-risk
populations. Whether changes in AS can predict prognosis in patients with symptomatic peripheral arterial
disease (PAD) has never been investigated. The aim of the present study was to test the hypothesis that AS is an
independent predictor of all-cause and cardiovascular disease (CVD) mortality in patients with symptomatic PAD.
Methods: A cohort of 117 symptomatic PAD patients (aged 62.3  7.7 years) were prospectively recruited from
the Department of Vascular Surgery, Tartu University Hospital, between 2002 and 2010. The AS was measured
using pulse wave analysis and assessment of pulse wave velocity (PWV).
Results: During the follow-up period (mean 4.1  2.2 years) there were 32 fatal events. KaplaneMeier analysis
showed that the probability of all-cause and CVD mortality decreased with increasing small artery elasticity (SAE),
as estimated by the log-rank test (p ¼ .004; p ¼ .005, respectively). By contrast, large artery elasticity,
augmentation index, and aortic and brachial PWV were not signiﬁcantly related to mortality. In a Cox
proportional hazard model, SAE above the median was associated with decreased all-cause and CVD mortality
after adjustment for confounding factors: relative risk (RR), 0.37; 95% conﬁdence interval (CI), 0.17e0.81;
p ¼ .01; RR, 0.11; 95% CI, 0.01e0.86; p ¼ .04, respectively).
Conclusions: This study provides the ﬁrst evidence, obtained from an observational study, that decreased small
artery elasticity is an independent predictor of all-cause and CVD mortality in patients with symptomatic PAD.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Lower extremity peripheral arterial disease (PAD) is a
manifestation of systemic atherosclerosis with a prevalence
of 2.7e3% in a population aged 45e49 years, increasing to
18.2% in persons aged 60e90 years.1e3 The association ofresponding author. J. Kals, Institute of Biomedicine and Trans-
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//dx.doi.org/10.1016/j.ejvs.2014.05.018PAD with increased future cardiovascular disease (CVD)
events and mortality, and total mortality has been
demonstrated in numerous studies.4,5 Possible explanations
for the PAD patients’ poor prognosis lie in accumulation of
classical CVD risk factors and in functional impairment and
progression of the disease.6,7 However, the exact mecha-
nisms by which PAD is associated with increased risk are not
fully understood. Therefore, identiﬁcation of novel prog-
nostic markers for PAD may improve understanding of the
mechanisms of atherosclerosis, which may ultimately lead
to new and better therapies.8
Altered arterial wall properties, such as arterial stiffness
(AS), might be one potential cause of poor prognosis in
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determinant of CVDevents,mortality and totalmortality,9 and
also plays an important role in atherosclerosis.10 Arterial
stiffeningmay induce arterial remodeling, wall thickening, and
development of atheroma. Moreover, AS may contribute to
ulceration and rupture of atherosclerotic plaques.11
Pulse wave analysis (PWA) and assessment of brachial
and aortic pulse wave velocity (PWV) are well established
methods for measuring AS. Increased aortic PWV and
augmentation index (AIx), and decreased small (SAE) and
large artery elasticity (LAE) in patients with PAD have been
demonstrated.12,13 Large-scale studies have shown that
increased aortic PWV and AIx, and decreased SAE are in-
dependent predictors of CVD, CVD events and mortality.9,14
Moreover, lower SAE and higher AIx were associated with
ankle-brachial index (ABI),15,16 which is the most powerful
indicator in PAD and is linked to survival.7
Only a few studies have estimated associations between
vascular function and prognosis in the setting of PAD.
Endothelial dysfunction predicts postoperative17 and long-
term CVD events in PAD patients.18e20 Furthermore,
whether changes in AS can predict all-cause and CVD
mortality in patients with symptomatic PAD has never been
investigated. The aim of the present study was to test the
hypothesis that AS is an independent predictor of all-cause
and CVD mortality in symptomatic PAD patients after con-
trolling for the classic CVD risk factors.
METHODS
Subjects and study design
This study was conducted within the framework of an
ongoing prospective study comparing vascular phenotype
and biomarkers in PAD patients living in Estonia. Patients
with PAD (Fontaine stages II-IV) were prospectively
recruited from the Department of Vascular Surgery, Tartu
University Hospital, Estonia, between October 2, 2002 and
May 24, 2010. The primary end point of this cohort study
was mortality (all-cause and CVD). The subjects were all
male with angiographically proven PAD deﬁned by occlusion
or stenosis of the arteries of the lower extremities. The ABI
was less than 0.90 (range 0.1e0.89). The patients’ exclusion
criteria included (based on clinical examination, ECG, and
blood tests): any concomitant acute or chronic inﬂamma-
tory disease, myocardial infarction, coronary revasculariza-
tion or cerebrovascular events during the past 6 months,
earlier revascularization procedures of the lower limb, up-
per limb occlusive arterial disease, cardiac arrhythmias, or
valve pathologies, diabetes mellitus, malignancies, and
renal failure. Demographic data including the risk factors for
CVD, were collected on the study entry day when the AS
indices, brachial and aortic PWV, AIx, SAE, and LAE, were
measured. Smoking status was deﬁned as current or past
versus never. This study was carried out in accordance with
the Declaration of Helsinki of the World Medical Association
and was approved by the ethics committee, University of
Tartu. Informed written consent was obtained from each
participant.Study protocol
The subjects were studied and the plasma samples were
collected after an overnight fast and abstinence from any
medications, tobacco, alcohol, and tea or coffee. After 15min
of rest in a quiet, temperature-controlled room, ABI, blood
pressure and PWV were measured and PWA was performed.
All hemodynamic recordings weremade in duplicate for each
time point. Thereafter, venous blood samples were drawn
from the antecubital fossa for measurement of glucose, total
cholesterol, low-density lipoprotein cholesterol (LDL-C)
cholesterol, high-density lipoprotein cholesterol (HDL-C),
triglycerides, high-sensitivity C-reactive protein (hsCRP),
creatinine, oxidized LDL-C (oxLDL), hemoglobin, and red
blood cells (RBC) count. Height and weight were recorded,
and body mass index (BMI) was calculated.Measurement of arterial stiffness and ABI
Peripheral blood pressure (BP) was measured from the both
arms using a validated oscillometric technique (OMRON
M4-I; Omron Healthcare Europe BV, Hoofddorp, The
Netherlands). The arterial waveform was measured in the
dominant arm by a Cardiovascular Proﬁling Instrument
(HDI/Pulse Wave CR-2000, Hypertension Diagnostics Inc,
Eagan, USA). This method of vascular assessment is based
on a modiﬁed 2-element Windkessel model that allows
calculation of SAE and LAE.21
The AIx and central hemodynamics were assessed by
systolic PWA using an Sphygmocor apparatus (SphygmoCor;
AtCor Medical, Sydney, Australia).12 Pulse pressure (PP)
ampliﬁcation (PPA) was expressed as the percentage in-
crease of PP in the peripheral (brachial) artery (PPP) relative
to central (aortic) PP (CPP), according to the formula:
PPA ¼ 100 (PPP-CPP)/CPP. Aortic and brachial PWV were
measured by sequentially recording ECG-gated carotid and
femoral or radial artery waveforms (SphygmoCor; AtCor
Medical, Sydney, Australia).12 The ABI was measured using
the Bidirectional Doppler MD 6 (D. E. Hokanson Inc, Belle-
vue, WA, USA). The mean of the two BP readings (from the
arm of which the BP values were higher) and the lower ABI
value of the two legs were included in statistical analysis.Biochemical analysis
The blood samples were centrifuged and the plasma was
divided into aliquots and stored at 70 C until analysis.
The plasma content of oxLDL was analyzed using a
competitive enzyme-linked immunoassay (ELISA) kit. Plasma
levels of glucose, hsCRP, total cholesterol, LDL-C, HDL-C,
triglyceride and creatinine, hemoglobin level, RBC count,
and glomerular ﬁltration rate were determined by standard
laboratory methods.Mortality
The follow-up period ended in August 4, 2011 (mean follow-
up, 4.1  2.2 years). The deceased subjects were identiﬁed
from Estonia mortality records and death was conﬁrmed
from the death certiﬁcate. All other subjects were
310 J. Kals et al.considered to be alive at the end of the follow-up period.
The causes of death were taken from the death certiﬁcate,
or by telephone interview with the subjects’ general prac-
titioner or relatives, and were coded in accordance with the
International Classiﬁcation of Disease (tenth revision).
Death as a result of acute myocardial infarction, non-
hemorrhagic stroke, or exacerbation of heart failure was
deﬁned as a CVD death.Population for analysis
Of the 123 subjects with a measurement of AS parameters,
ﬁve were excluded from the analyses because of poor
quality of the AS index recordings, leaving 118 subjects. One
subject was excluded with unknown cause of mortality,
leaving 117 subjects for analyses.
Statistical analysis
Power calculation is based on the expected 20% difference
in PAD survival according to the SAE value. This implies
that about 120 subjects have to be included (two sided
test, b ¼ .2 at a ¼ .05; RR ¼ 0.3). Data were collected and
analyzed using the software R, version 2.15.2 for Windows.
All data were tested for normality of distribution, and log
transformation and/or nonparametric tests were used
where appropriate. Continuous data are expressed as
mean  SD if distributed normally, or otherwise, as me-
dian with the 25% and 75% percentiles. Dichotomous
variables are given as prevalence in number and percent-
age. Relationships of the AS parameters and potential
confounders with all-cause and CVD survival were esti-
mated using the chi-square test for categorical variables
and the Student t test or the ManneWhitney test for
continuous variables that had a normal or skewed distri-
bution, respectively. Survival was assessed by the Kaplane
Meier curves and was compared by the log-rank test ac-
cording to the median of the AS parameters. For the AS
parameters, additional adjustments were made for MAP
and heart rate. To evaluate whether oxLDL levels or RBC
count added to the predictive value of AS, the study
population was divided into eight groups: patients with
SAE higher than the median and oxLDL or RBC count lower
than the median, those with both SAE and oxLDL or RBC
count higher than their respective median values, those
with both SAE and oxLDL or RBC count lower than their
respective median values, and those with SAE lower than
the median value and oxLDL or RBC count higher than the
median value. A Cox proportional hazards regression
model was then used to control for the confounders
identiﬁed by univariate analysis (inclusion criteria p < .1).
The proportional hazards assumptions were satisﬁed.
Receiver-operating characteristic (ROC) curves were
employed to compute the discriminatory power of
different sets of prognostic factors. Differences in the
discriminatory power between models were estimated by
a nonparametric approach to the analysis of areas under
the ROC curves using the theory on generalized U
statistics.RESULTS
Patients with PAD
In the 117 patients studied, 75 had stage II, 29 stage III, and 13
stage IV chronic ischemia as deﬁned by Fontaine. Forty-six
patients (39.3%) with arterial hypertension and 23 patients
(19.7%) with coronary artery disease as the co-morbidity
were included in the study. A non-signiﬁcant proportion of
the patients used concomitant medications: 46 patients used
pentoxifylline; 31 patients, aspirin; 14 patients, statins; 18
patients, angiotensin-converting enzyme inhibitors; 19 pa-
tients, calcium channel blockers; 11 patients, angiotensin-
receptor blockers; eight patients, beta-blockers; and ﬁve
patients, diuretics.Themean duration of the follow-up period
was 4.1  2.2 years. During that time there were 32 fatal
events: 10 (31.3%) patients had a CVD death; two (6.3%) died
because of acutemyocardial infarction, one (3.1%) had a fatal
ischemic stroke, and seven (21.9%) patients died because of
exacerbation of chronic heart failure.The baseline clinical and
biochemical characteristics of the survivors and non-
survivors are presented in Table 1. As is evident, the non-
survivors have lower BMI, hemoglobin, and RBC count, and
higher oxLDL values. The non-survivors also had a lower
glucose value; however, the glucose level is within a normal
range in both groups.Arterial stiffness and all-cause and cardiovascular disease
mortality
The AS parameters for the survivors and non-survivors are
presented in Table 2. By univariate analysis, lower SAE and
PPP, and higher AIx and AIx@75 were associated with
increased all-cause mortality. The LAE, brachial and aortic
PWV, AP, and CPP for the study groups were comparable.
Lower PPA showed a trend to association with higher all-
cause mortality (p ¼ .08). As the KaplaneMeier survival
curves demonstrate (Fig. 1), the incidence of all-cause (left)
and CVD (right) deaths during follow-up was higher in PAD
patients with SAE below the median value than in those
with SAE above the median value. In the log-rank test, all-
cause but not CVD mortality was related to AIx@75
(p ¼ .04; p ¼ .89, respectively). The oxLDL was related to
CVD mortality (p ¼ .01), but remained with borderline
signiﬁcance for all-cause mortality (p ¼ .08). Conversely,
when the population was divided according to the median
value of LAE, brachial and aortic PWV and AIx, all-cause
survival probability was not associated with AS (p ¼ .19,
p ¼ .89, p ¼ .73, p ¼ .24, respectively). The variables that
met the entry criterion (p ¼ .1 in univariate analysis) were
included in the Cox proportional hazard model: BMI, pe-
ripheral systolic BP, glucose, hemoglobin, RBC count, oxLDL,
SAE, AIx, AIx@75, PPP, and PPA. The independent signiﬁcant
predictors of all-cause and CVD mortality were SAE and RBC
count (Table 3).
The results of an additional KaplaneMeier analysis for
the four subgroups of PAD patients divided according to the
median values of SAE and oxLDL or RBC count are shown in
Fig. 2. The analysis revealed that oxLDL and RBC slightly
Table 1. Clinical and biochemical characteristics of the study population.
Characteristic Survivors
(n ¼ 85)
Non-survivors
(n ¼ 32)
p Value
Age (years) 61.8  8.1 62.9  6.5 .43
Body mass index (kg/m2) 25.2  4.1 23  2.9 .001
Coronary heart disease, n (%) 17 (20) 6 (19) 1.0
Hypertension, n (%) 31 (36) 15 (47) .42
Smoking (past þ current), n (%) 83 (98) 31 (97) 1.0
Peripheral systolic BP (mmHg) 141 (128e158) 135 (128e142) .08
Peripheral diastolic BP (mmHg) 78 (73e84) 80 (74e83) .62
Central systolic BP (mmHg) 129 (119e142) 126 (121e133) .35
Central diastolic BP (mmHg) 79 (75e85) 80 (75e85) .65
Mean arterial pressure (mmHg) 99 (93e109) 98 (92e106) .53
Heart rate (beats per minute) 66 (59e72) 67 (61e74) .79
Ankle-brachial index 0.5 (0.3e0.6) 0.4 (0.1e0.5) .17
Total cholesterol (mmol/L) 5.9  1.2 5.9  1.1 .92
HDL-cholesterol (mmol/L) 1.3 (1e1.4) 1.3 (1.1e1.4) .31
LDL-cholesterol (mmol/L) 4.2  1.1 4  1.2 .36
Triglycerides (mmol/L) 1.6 (1.3e2.1) 1.4 (1.2e1.7) .16
Glucose (mmol/L) 5.5 (4.9e5.9) 5 (4.8e5.4) .009
hsCRP (mg/L) 2.9 (1.1e7.7) 4.6 (2e7.7) .16
Creatinine (mmol/L) 78 (68e85) 72 (64e82) .25
GFR (mL/min/1.73 m2) 97 (85e111) 100 (88e116) .61
Hemoglobin (g/L) 149.5  14.9 141.4  16.7 .02
Red blood cells count (x 1012/L) 4.9 (4.5e5.1) 4.7 (4e4.9) .009
oxLDL (U/L)a 78 (57e111) 128 (95e177) .001
Values are mean (SD), median (with 25% and 75% percentiles) or prevalence (%). BP, blood pressure; hsCRP, high-sensitivity C-reactive
protein; GFR, glomerular ﬁltration rate; oxLDL, oxidized low-density lipoprotein cholesterol.
a Values are available for 113 patients.
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by Cox analysis. Compared with patients with SAE above the
median value and oxLDL below the median value, those
with both SAE and oxLDL above the median value showed a
1.8-fold increase in the all-cause mortality risk (95% CI
0.45e7.32, p ¼ .41). Also, patients with both SAE and oxLDL
below the median value showed a 2.7-fold increase in the
risk (95% CI 0.59e11.99, p ¼ .20). The highest risk for future
all-cause mortality was observed in patients with SAE below
the median value and oxLDL above the median value (RR
4.6, 95% CI 1.33e15.86, p ¼ .02). Compared with patients
with both SAE and RBC count above the median value,
those with SAE above the median and RBC below the me-
dian value had a 1.9-fold increase in risk (95% CI 0.48e7.7,
p ¼ .36). Patients with SAE below the median value andTable 2. Arterial stiffness parameters of the study population.
Characteristic Survivors
(n ¼ 85)
LAE index (mL/mmHg10) 12.1 (8.8e15.6
SAE index (mL/mmHg100) 2.9 (2.3e3.8)
Augmentation index (%) 32 (26e39)
Augmentation index@75 (%) 28.1  8.5
Aortic PWV (m/s) 10  2.5
Brachial PWV (m/s) 8.8  1.4
Augmentation pressure (mmHg) 16.5  6.9
Peripheral pulse pressure (mmHg) 61 (53e70)
Central pulse pressure (mmHg) 50 (43e57)
Pulse pressure ampliﬁcation 23 (16e30)
Values are mean (SD), median (with 25% and 75% percentiles) or pre
PWV, pulse wave velocity.RBC above the median value had a 4.1-fold increase in risk
(95% CI 1.13e14.89, p ¼ .03). The highest risk for future all-
cause mortality was observed in patients with both SAE and
RBC count below the median value (RR 4.6, 95% CI 1.3e
16.0, p ¼ .02).
The area under the ROC curve (Fig. 3) was 0.70 for the
model on the basis of age, BMI, smoking, total choles-
terol, HDL-C, glucose, mean arterial pressure (MAP), heart
rate, and ABI. When SAE and oxLDL were added to this
model, the discriminatory power improved up to 0.82
(p ¼ .006).
DISCUSSION
The present study is the ﬁrst to evaluate the prognostic
impact of AS in patients with symptomatic PAD. The mainNon-survivors
(n ¼ 32)
p Value
) 12.4 (10e15.1) .73
2.1 (1.8e2.8) <.001
38 (31e41) .03
31.7  7.2 .03
10.2  2.1 .78
8.7  1 .77
17.7  5.5 .31
58 (51e62) .04
47 (42e52) .20
20 (13e24) .08
valence (%). LAE, large artery elasticity; SAE, small artery elasticity;
Figure 1. KaplaneMeier plots showing the relationship between survival and small artery elasticity (SAE) higher and lower than median
values. Left, analysis including all deaths survival curves differ in the median value of SAE. Right, analysis including deaths from cardio-
vascular disease survival curves differ in the median value of SAE.
312 J. Kals et al.novel ﬁnding is that there exists a direct independent
relationship between SAE and all-cause and CVD mortality
in a cohort of symptomatic patients with PAD. The results
indicate that decreased elastic properties of the small
muscular arteries is an independent predictor of all-cause
and CVD mortality in patients with symptomatic PAD.
The present results are in good agreement with previous
data. Wan et al. demonstrated that the probability of a CVD
event or CVD death in patients with coronary artery disease
increased with a decrease in SAE.22 A prospective analysis
of participants who were initially free from symptomatic
CVD demonstrated that SAE provided predictive informa-
tion about myocardial infarction, coronary heart death,
angina, heart failure, stroke, and PAD.23 Lower SAE was
incrementally associated with the incidence of hypertension
among normotensive adults free from CVD24 and CVD
events independently of age.14 Both SAE and LAE were
associated with subclinical coronary atherosclerosis in a
multi-ethnic middle-aged cohort free from CVD.25
Although patients with PAD are at an increased CVD risk
compared with age-matched controls, only a few studies
have been conducted to demonstrate associations between
vascular function and outcome in PAD patients. Impaired
brachial artery endothelial function independently predicts
postoperative17 and long-term CVD events,18,19 as well as
adding to the prognostic value of ABI in PAD patients.20
Increased AS has been reported in patients with PAD
compared with age-matched controls,12,13 and there is aTable 3. Independent predictors of all-cause and cardiovascular diseas
Characteristic Relative r
All-cause mortality
SAE above median (mL/mmHg100) 0.37
Red blood cells count (1012/L) 0.52
Cardiovascular disease mortality
SAE above median (mL/mmHg100) 0.11
Red blood cells count (1012/L) 0.34
SAE, small artery elasticity; CI, conﬁdence interval.link between increased AS and atherosclerotic complica-
tions.9 However, there are no data about an association
between AS and outcome in PAD patients. The main novel
ﬁnding in this study that lower SAE predicts all-cause and
CVD mortality in PAD patients after adjustment for poten-
tial confounders, emphasizes the pathophysiological link
between AS and clinical outcome in patients with systemic
atherosclerosis.
Several mechanisms can account for the association be-
tween increased AS and worse outcome in patients with
PAD. The AS may favor fatal cardio- and cerebrovascular
events through acceleration of atherosclerosis and increase
of CPP.26 Elevated PP may also induce arterial remodeling
by increasing wall thickness, and promoting development of
plaques.10 Higher PP is independently associated with
arterial plaque ulceration in patients with symptomatic
carotid stenosis, supporting the hypothesis that cyclical
hemodynamic forces are important determinants of plaque
rupture.11 Elevated central BP and thromboembolism,
subsequent to plaque rupture caused by stiff arteries, may
explain the association between increased AS and poor
outcome in patients with atherosclerosis.
Wilkins et al. demonstrated that decreased SAE was
signiﬁcantly associated with lower ABI values in apparently
healthy persons, whereas LAE was less strongly associated
with ABI.15 The ABI also correlated with SAE in patients with
PAD but its association with LAE was only borderline.27
Although PAD is primarily a disease of the large musculare mortality.
isk 95% CI p Value
0.17e0.81 .01
0.29e0.92 .03
0.01e0.86 .04
0.13e0.91 .03
Figure 2. Left, KaplaneMeier survival curves for a subgroup of patients showing higher or lower than the median values of small artery
elasticity (SAE) and oxidized LDL (oxLDL). A combination of lower than median SAE and higher than median oxLDL is associated with the
highest risk for future all-cause mortality. Right, KaplaneMeier survival curves for a subgroup of patients showing higher or lower than the
median values of small artery elasticity (SAE) and red blood cells (RBC) count. Patients with SAE below the median value and RBC count
above the median value had a signiﬁcantly increased risk of future all-cause mortality. The highest risk was observed in patients with both
SAE and RBC count below the median value.
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SAE, which represents the oscillatory or reﬂective compo-
nent of the small muscular arteries and arterioles, indicates
a speciﬁc link between changes in the distal vascular bedFigure 3. Receiver-operating characteristic (ROC) analysis of the
conventional risk factors (age, BMI, smoking, total cholesterol,
HDL-C, glucose, MAP, heart rate, ABI), small artery elasticity (SAE)
and a combination of SAE and oxidized LDL (oxLDL). The area under
the ROC curve for 4.1-year mortality is the lowest for only the
conventional risk factors (0.70, 95% CI 0.60e0.80 (model 1)), fol-
lowed by a combination of the conventional risk factors with SAE
(0.78, 95% CI 0.68e0.87 (model 2)), and the highest for a com-
bination of the conventional risk factors with SAE and oxLDL (0.82,
95% CI 0.73e0.92 (model 3)). Model 1 vs. Model 2 (p ¼ .03);
Model 1 vs. Model 3 (p ¼ .006); Model 2 vs. Model 3 (p ¼ .14).and global and CVD mortality risk. The ﬂow of blood into
the lower extremities depends not only on the severity of
atherosclerosis but also on the regulatory mechanisms that
govern the microcirculatory blood ﬂow, including modula-
tion of vasodilator and vasoconstrictor activity in skeletal
muscle. In the advanced stages of PAD, microvascular ab-
normalities become more prominent, representing inade-
quate compensatory collateral circulation, and may
contribute to the symptomatology of the disease.28 Stiff-
ening of the small arteries alters the magnitude and timing
of reﬂected waves and increases central BP and left ven-
tricular afterload. Thus, a decrease of SAE, rather than
changes in the mechanical properties of the large muscular
arteries supplying the lower extremity exerts a stronger
impact on the association of vascular dysfunction with
severity and outcome in patients with PAD.
Abnormal large artery stiffness is associated with major
CVD end points, including heart disease, stroke, and chronic
kidney disease. However, this study failed to ﬁnd an asso-
ciation between LAE and aortic PWV, the gold standard
measure of AS, in PAD patients’ prognosis. Nor did the
recent PARTAGE study ﬁnd signiﬁcant association between
aortic PWV and total mortality or major CVD events, while
only lower PPA was associated with poor prognosis in the
very elderly.29 Brand et al. showed that aortic PWV was
markedly attenuated in patients with advanced PAD and an
index of the central PP/aortic PWA mismatch predicted the
presence of critical limb ischemia better than alternative
vascular indices.30 This study demonstrated that RBC count
itself predicts all-cause and CVD mortality, and RBC count as
well as oxLDL adds to the predictive value of SAE in
determining the risk for all-cause mortality in patients with
PAD. Previous studies have shown that oxLDL is a predictor
314 J. Kals et al.of all-cause mortality31 and improves the reclassiﬁcation
capacity of Framingham-derived risk functions.32 Anemia is
also a common and an independent prognostic factor for
mortality in CVD patients.33 There are several limitations to
the present study. First, the study examined male subjects
with established atherosclerosis and the ﬁndings may not
be generally applicable. Second, a limitation of this study is
the potential confounding effect of smoking and medica-
tions on AS. Third, measures of central hemodynamics,
arterial stiffness, and Windkessel-derived arterial elasticity
indices may be subject to substantial under- or over-
estimation in patients with PAD caused by luminal stenosis
in various arterial segments.30 Fourth, the cause of death
was obtained from death certiﬁcates using a telephone
interview with the patients’ general practitioners or rela-
tives. A recent systematic review emphasizes the need to
improve global methodologies of mortality measurement,
because of long-held discrepancies between clinical and
postmortem diagnosis.34 Finally, the small number of sub-
jects is also a potential limitation of the study.
CONCLUSIONS
This study provides the ﬁrst evidence, obtained from an
observational study, that decreased small artery elasticity is
an independent predictor of all-cause and CVD mortality in
patients with symptomatic PAD. This ﬁnding further sup-
ports the relevance of arterial dysfunction in progression of
CVD and suggests that symptomatic PAD patients with
stiffer arteries are at an increased risk of all-cause and CVD
mortality. Non-invasive arterial phenotype testing might
improve prediction of prognosis and have clinical utility for
management of patients with systemic atherosclerosis.
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